Table 5 The Ongoing clinical trials with Carbon ion or Proton therapy. Source: (Clinicaltrials.gov) or (www.ptcog.ch), updated November 2022
From: Charged particle therapy for high-grade gliomas in adults: a systematic review
Study title | ID | Sponsor | Pathology | Phase | Arms |
|---|---|---|---|---|---|
Carbon ion radiotherapy for primary Glioblastoma (CLEOPATRA) | NCT01165671 | University Hospital Heidelberg | Glioblastoma | II | Photon(48–52 Gy) with concurrent TMZ plus Carbon ion boost (18GyE in 6 fractions) or Proton boost (10GyE in 5 fractions) |
Proton and heavy ion beam vs. photon beam radiation for newly diagnosed Glioblastoma | NCT04536649 | Shanghai Proton and Heavy Ion Center | Glioblastoma Anaplastic astrocytoma | III | Arm A: Standard-dose photon therapy (60 Gy in 30 fractions for high-risk area) plus TMZ; Arm B: Standard-dose Proton therapy (60GyE in 30 fractions for high-risk area) plus TMZ; Arm C: Carbon-ion boost (15GyE in 3 fractions for residual lesion) plus Standard-dose Proton therapy (60 Gy in 30 fractions for high-risk area) plus TMZ |
Dose-escalated photon or proton therapy vs. standard-dose Photon therapy and TMZ for newly diagnosed Glioblastoma | NCT02179086 | NRG Oncology | Glioblastoma | II | Arm A (control): Standard-dose photon therapy (60 Gy in 30 fractions for high-risk area) plus TMZ; Arm B (experiment): Dose-escalated Photon therapy Arm C (experiment): Dose-escalated Proton therapy |
Proton Radiation Therapy for Gliomas | NCT01358058 | Massachusetts General Hospital | WHO Grade 3 Glioma with IDH1 mutation or 1p/19q codeletion | Not applicable | Single arm study delivering fractionated proton therapy over 6 week (54–59.4 Gy (RBE) at 1.8 Gy (RBE)) |
Proton or IMRT in Preserving Brain Function in Patients with IDH Mutant Grade II or III Glioma | NCT03180502 | NRG Oncology | WHO Grade 3 Glioma with IDH1/2 mutation or 1p/19q codeletion | II | Arm A (control): Standard-dose Photon therapy (60 Gy in 30 fractions for high-risk area) plus TMZ; Arm B (experiment): Standard-dose Proton therapy (60 Gy in 30 fractions for high-risk area) plus TMZ; |
Proton Radiotherapy for Primary Central Nervous System Tumors in Adults | NCT02797366 | Uppsala University | WHO Grade 3 Glioma with IDH1 mutation or 1p/19q codeletion | Not applicable | Single arm study delivering Proton radiation therapy daily (Monday through Friday) for 4–8 weeks |
Comparison of Proton and Photon Radiotherapy of Brain Tumors | NCT02824731 | Technische Universität Dresden | High-grade Glioma | Not applicable | Single arm study delivering fractionated proton therapy (54–60 Gy (RBE) at 2.0 Gy (RBE)) |